Announcements Trials
Browse Landscape

Phase

Phase 3 28Phase 2 14Phase 4 12Phase NA 5Phase 1/2 3Phase 1 3Phase 2/3 2

Status

Unknown 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Prostatic Neoplasms 2Breast Neoplasms 2Osteosarcoma 1Metastatic Breast Cancer With Bone Involvement 1Insulin Resistance 1

Interventions

Capecitabine 16Paclitaxel 12Docetaxel 10Cyclophosphamide 10Epirubicin 8Gemcitabine 7Letrozole 6Doxorubicin 6Carboplatin 6Trastuzumab 5Vinorelbine 4Cisplatin 4pertuzumab 3exemestane 3Neoadjuvant Therapy 3Drug Therapy 3Ado-Trastuzumab Emtansine 3AC protocol 3130-nm albumin-bound paclitaxel 3apatinib 2Zoledronic Acid 2Thiotepa 2Taxes 2Tamoxifen 2Standard of Care 2Radiosurgery 2Melatonin 2Lapatinib 2Injections 2Goserelin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Breast Neoplasms × Zoledronic Acid × Clear all
NCT01654367 2012-07-31

esozao

Tianjin Medical University

Phase 2/3 Unknown
300 enrolled
Breast

Breast Neoplasms

NCT00524849 2010-09-14

Zometa and Circulating Vascular Endothelial Growth Factor (VEGF) in Breast Cancer Patients With Bone Metastasis

Fudan University

Phase 2/3 Completed
60 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡